Introduction
Lung cancer is the leading cause of cancer-related death worldwide [1] . Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers [2] , and it is characterized by rapid tumor growth and early metastasis to multiple organs. Response to initial chemotherapy is generally good; however, the majority of patients develop recurrence and the prognosis of such patients remains poor [3] . Recently, a strategy of maintenance chemotherapy has been established for non-small-cell lung cancer (NSCLC) and is currently recommended as a standard treatment in clinical guidelines [4, 5] ; however, cumulative data have indicated that this maintenance strategy is not effective for SCLC.
Case Report
A 58-year-old Japanese man was referred to our hospital due to a dry cough continuing for over 3 weeks. He was a former smoker with a 45 pack-year history. Chest X-ray showed left pleural effusion and consolidation in the left hilum. Computed tomography (CT) of the chest revealed left pleural effusion and a large tumor of about 120 mm invading the aorta and main pulmonary artery directly ( fig. 1 ). He was diagnosed with SCLC based on pleural effusion cytology. The serum concentration of neuron-specific enolase had increased to 24.8 ng/ml, and pro-gastrin-releasing peptide had also increased to 987.5 pg/ml. Abdominal CT, whole-body bone scintigraphy and brain magnetic resonance imaging did not reveal any distant metastasis. Therefore, the clinical stage of his disease was determined as T4N2M1a, stage IV. Four cycles of chemotherapy, consisting of cisplatin and irinotecan, were performed and a partial response was achieved ( fig. 2 ). Neuron-specific enolase and pro-gastrinreleasing peptide levels decreased to the normal range. Toxicity was quite mild and the patient had a strong wish to continue chemotherapy. Therefore, we started maintenance chemotherapy with irinotecan after the initial treatment. The patient underwent 24 cycles of maintenance treatment with irinotecan without marked toxicity. Subsequently, 2 years and 6 months after the initial diagnosis, 18 F-fluorodeoxyglucose positron emission tomography showed no positive sign of disease; the main tumor, lymph nodes, and pleural effusion had completely disappeared and the response was defined as a complete response ( fig. 3 ). Based on these results, we decided to withdraw chemotherapy. Currently (3 years since the initial diagnosis), disease relapse has not been documented and the patient is still alive without any complaints.
Discussion
Recent meta-analyses have shown that thoracic radiotherapy with concurrent chemotherapy resulted in a 5-year survival rate of 20-30% in patients with limited disease; however, long-term survivors with extensive disease are extremely rare [6] . Consequently, the majority of SCLC patients inevitably develop recurrence. Currently, topotecan is the only drug approved by the US Food and Drug Administration for relapsed SCLC, and is considered the standard second-line chemotherapy in many countries [7] . More recently, amrubicin has also shown promising antitumor activity in this setting [8, 9] ; however, the prognosis of such patients remains dismal. Although maintenance chemotherapy has been extensively investigated for NSCLC and is currently recommended as a standard treatment in clinical guidelines [4, 5] , the strategy has not been established for SCLC. However, previous studies tested only old agents, and newer agents such as irinotecan and amrubicin have not been investigated in the maintenance setting. Considering that the maintenance strategy succeeded in NSCLC using newer agents, such as pemetrexed and erlotinib, which are more effective and less toxic than older agents, newer agents for SCLC, such as irinotecan, topotecan, and amrubicin, should also be investigated in the maintenance setting for SCLC. To our knowledge, only one study has investigated the efficacy of irinotecan as maintenance chemotherapy in SCLC [10] . Although the results of the study were negative, our successful case indicates that maintenance strategy may merit further investigation for patients with SCLC.
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